Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaad.2004.07.043 | DOI Listing |
J Am Acad Orthop Surg
January 2025
From the Department of Orthopaedics, Washington University School of Medicine, St. Louis, MO.
Introduction: Despite the high effectiveness of Ponseti casting in treating idiopathic clubfoot, patient-reported outcomes (PROs) are not studied well in the literature, necessitating further investigation into PROs to evaluate the effect on patients' lives. We used the Patient-Reported Outcomes Measurement Information System (PROMIS) to evaluate PROs in children with Ponseti-treated clubfoot and assess the effect of recurrence on these PROs.
Methods: This study retrospectively reviewed medical records from patients ages 5 to 18 years treated for idiopathic clubfoot at a single institution from 2002 to 2023 with available PROMIS data for mobility, pain, and peer relationships.
Cancer Nurs
January 2025
Author Affiliations: Department of Health and Clinical Sciences, University of Michigan School of Nursing (Dr Knoerl and Mss Smener and Grandinetti); Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School (Drs Fecher, Henry, Karimi, Pettit, and Schuetze); Pediatric Hematology/Oncology, C.S. Mott Children's Hospital (Dr Walling); and School of Social Work, University of Michigan (Dr Zhang), Ann Arbor; and College of Nursing, The University of Tennessee, Knoxville (Dr Barton).
Background: Most studies to date exploring facilitators and barriers to adolescent and young adults' (AYAs') participation in clinical trials have been focused on external factors to AYAs' participation or recruitment strategies.
Objective: The purpose of this mixed-methods study was to determine AYA cancer survivors' preferences for oncology symptom management clinical trial participation.
Methods: Semistructured interviews and conjoint analysis were conducted to clarify potential attributes (eg, characteristics) and levels (eg, value of the characteristic) that may be important to AYA cancer survivors when considering clinical trial participation (n = 19).
Blood Adv
February 2025
Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA.
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with newly diagnosed AML using data from a nationwide electronic health record-derived deidentified database. Patients were categorized based on their diagnosis date relative to venetoclax approval, as pre-novel therapy era (Pre era; 2014-2018; n = 2998) or post-novel therapy era (Post era; 2019-2022; n = 2098).
View Article and Find Full Text PDFIndian J Pediatr
January 2025
Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Objectives: To compare six doses of intrapleural streptokinase (SK) vs. the conventional three doses in children with empyema.
Methods: In this randomized controlled trial, children with empyema received intrapleural streptokinase, either twice daily for 3 d (total 6 doses); or once daily for 3 d (total 3 doses).
Eur Arch Paediatr Dent
January 2025
Department of Paediatric Dentistry, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece.
Purpose: Assess the knowledge and attitudes of parents/guardians regarding their children's oral health and their preferences regarding the treatment of carious primary teeth.
Methods: A cross-sectional study including the completion of a questionnaire by parents/guardians of healthy children aged 2-12 years attending the Department of Pediatric Dentistry (NKUA). Data were collected through 35 questions regarding demographic characteristics of the participants, oral hygiene and dietary habits, and parents' knowledge of the importance of oral health and primary teeth.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!